APA (7th ed.) Citation

FJ, L., LC, G., HZ, L., ZW, Z., HY, L., SG, X., . . . JD, H. (2025). Dihydroisotanshinone I regulates ferroptosis via PI3K/AKT pathway to enhance cisplatin sensitivity in lung adenocarcinoma. The Journal of pharmacy and pharmacology, 77(6), 752. https://doi.org/10.1093/jpp/rgae085

Chicago Style (17th ed.) Citation

FJ, Li, Gao LC, Long HZ, Zhou ZW, Luo HY, Xu SG, Dai SM, and Hu JD. "Dihydroisotanshinone I Regulates Ferroptosis via PI3K/AKT Pathway to Enhance Cisplatin Sensitivity in Lung Adenocarcinoma." The Journal of Pharmacy and Pharmacology 77, no. 6 (2025): 752. https://doi.org/10.1093/jpp/rgae085.

MLA (9th ed.) Citation

FJ, Li, et al. "Dihydroisotanshinone I Regulates Ferroptosis via PI3K/AKT Pathway to Enhance Cisplatin Sensitivity in Lung Adenocarcinoma." The Journal of Pharmacy and Pharmacology, vol. 77, no. 6, 2025, p. 752, https://doi.org/10.1093/jpp/rgae085.